Corcept Therapeutics Inc (CORT) FinancialsCORTCorcept Therapeutics Inc

Evaluating the bottom line, Corcept Therapeutics Incorporated maintains a gross margin of 98.41%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 16.12%, while the net margin is 16.78%. These profitability ratios, combined with a Return on Equity (ROE) of 8.23%, provide a clear picture of how effectively CORT converts its operational activities into shareholder value.

In the context of the broader market, CORT competes directly with industry leaders such as MDGL and AAPG. With a market capitalization of $12.37B, it holds a significant position in the sector. When comparing efficiency, CORT's gross margin of 98.41% stands against MDGL's 89.02% and AAPG's 96.12%. Such benchmarking helps identify whether Corcept Therapeutics Incorporated is trading at a premium or discount relative to its financial performance.

Corcept reported a revenue of $256.1 million in Q2 2026, with a net income of $43 million, showing strong financial performance despite a recent dip in earnings.